Heart Failure Flashcards

1
Q

Heart Failure =

A

Complex clinical syndrome characterized by abnormalities of left ventricular function and neurohormonal regulation accompanied by effort intolerance, fluid retention and decreased longevity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

CV Causes of Heart Failure

A

Ischemic heart disease
Toxic cardiomyopathy such as alcohol or chemotheraputic agents
Idiopathic cardiomyopathies such as dilated, hypertrophic or restricted
Hypertension
Vavular heart disease
Pericardial disease
Congenital defects
Chronic tachycardia such atrial fibrillation with rapid ventricular response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Noncardiac Causes

A

Endocrine or metabolic disorders (high output heart failure)
Thyrotoxicosis
Anemia
Pregnancy
Fever, sepsis
Vitamin B1 deficiency
Connective tissue diseases such as lupus, polymyositis or scleroderma
Pulmonary diseases such as pulmonary HTN or cor pulmonale secondary to COPD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Pathophysiology

A

Decline in the heart’s ability to pump enough blood at a sufficient rate to sustain the body’s physiological functions (systolic heart failure) or elevated filling pressures (diastolic heart failure)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Diastolic Dysfxn

A

Increased ventricular stiffness and reduced compliance
Produces a rise in in cardiac pressures during diastole filling and the inability of the left ventricle to relax and accommodate a sufficient amount of blood from lungs
Left ventricular distendability is reduced during diastole and filling pressures must increase to maintain a constant ventricular volume
Results in an increase in cardiac filling pressures during rest and activity, failure of normal rise in cardiac output during exertion and reduction in cardiac output at rest
Most common causes are HTN, left ventricular hypertrophy, CAD, aortic stenosis and infiltrative or restrictive cardiac diseases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Systolic Dysfxn

A

Most common type of heart failure
3 determinants of ventricular dysfunction are altered preload, contractility and afterload
Preload is degree of myocardial fiber stretch at the end of ventricular filling. In systolic heart failure, the myocardial fibers are both excessively overloaded and stretched beyond lengths commensurate with the normal reflex-increased force of contraction. Cardiac output eventually falls
Ventricular dysfunction causes a decrease in myocardial contractility and causes a reduction in ejection fraction, stroke volume and cardiac output
Afterload is the amount of left ventricular wall tension that develops during systole to eject blood. Because afterload determines the ease or speed of ventricular contraction, the ejection fraction is a function of afterload

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Compensatory Mechanisms

A

Sympathetic adrenergic activity
Neuroendocrine activation
Ventricular remodeling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Classification

A

Class I: No limitations. Ordinary physical activity does not cause undue fatigue, dyspnea or palpitations
Class II: Slight limitation of physical activity. Such patients are comfortable at rest. Ordinary physical activity results if fatigue, palpitations, dyspnea or angina
Class III: Marked limitation of physical activity. Although patients are comfortable at rest, less than ordinary activity will lead to symptoms
Class IV: Inability to carry on any physical activity without discomfort. Symptoms are present at rest. With any physical activity, increased discomfort is experienced

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Clinical Presentation: Right-sided failure

A
Signs of fluid retention predominate
Elevated jugular venous pressure
Abdominal bloating and fullness
Hepatomegaly
Elevated liver enzymes due to passive liver congestion
Peripheral edema
Nocturia
Feeling bloated/anorexia
OSA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Clinical Presentation: Left-sided Failure

A
Have symptoms of low cardiac output and elevated pulmonary venous pressure
Dyspnea-predominant symptom
Fatigue
Orthopnea
Paroxysmal nocturnal dyspnea
Bronchospasm and wheezing 
Crackles
Hemoptysis and dysphasia
Pulmonary edema
Pleural effusion
Extra heart sounds S3 or S4
Lateral displacement of apical impulse
Murmurs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Dx Tests

A

BNP - elevated when ventricular filling pressures are high
CXR - cardiomegaly
Echocardiography - gold standard for dx HF
Exercise testing
Cardiac Catheterization
Cardiac MRI
Routine labs: CBC, CMP, thyroid studies, autoimmune studies if indicated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

DD

A
Chronic pulmonary conditions
PNA
Asthma/URI
Airway obstructions
OSA
Pleural effusions
Pulmonary embolism
Neuromuscular disorders
Anxiety
Depression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Treatment goals

A

Prevention of further myocardial injury
Prevention of recurrence of clinical failure
Relief of symptoms and signs
Improvement of prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pharm Tx

A

Therapy for heart failure can be subdivided by pathophysiology (systolic vs. diastolic dysfunction) and by the symptomatic presentation defined by the NYHA classification
With an ejection fraction < 40%, treatment is based on volume status. No evidence of fluid excess, start therapy with an ACE inhibitor
Once ACE dose is stabilized, start a beta blocker
If evidence of fluid overload, start ACE inhibitor and loop diuretic. Digoxin may be started to reduce symptoms and increase exercise tolerance. Once fluid overload is stabilized, a beta blocker should then be added

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

ACE-Is

A

Cornerstone of chronic management of heart failure
By suppressing the production of angiotension II, a potent vasoconstrictor, ACE inhibitors decrease systemic and pulmonary vascular resistance by preventing the release of aldosterone and norepinephrine while elevating the levels of vasodilator hormone bradykinin
Potential counterindications include history of compelling intolerance or adverse reaction, serum potassium greater than 5.5, serum creatinine >3.0 or worsening renal function and SYMPTOMATIC hypotension
ACE inhibitors have been shown to significantly reduce mortality, improve functional status and reduce hospital readmissions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

ARBs

A

Act directly on the angiotension-renin-aldosterone system. Modify the effects of angiotension II, the substance that promotes vasoconstriction, abnormal cell growth and the release of aldosterone
Use for patients unable to tolerate ACE inhibitors or in addition to ACE inhibitor
Potential counterindications same as ACE inhibitor

17
Q

Hydralazine and Nitrates

A

Combination of hydralazine and nitrates used for patients who ACE inhibitors are absolutely counterinicated
Hydralazine is a direct arterial vasodilator and nitrates are venous dilators that result in increased cardiac output secondary to decreased impedance to ventricular ejection and preload
Can improve survival and exercise tolerance in patients with heart failure
Frequent side effects that include headache, palpitations and nasal drainage
Can cause significant hypotension or orthostatic hypotension and doses need slow titration

18
Q

Beta Blockers

A

produce a substantial rise in ejection fraction averaging 10% over a 6-month period
Initiate gradually and with care to avoid deterioration in heart failure
Counterinicated in patients with acute exacerbations of failure, reactive airway disease and severe bradycardi

19
Q

Diuretics

A

Most effective means of preventing symptomatic relief to patients with moderate to severe heart failure
Mild fluid retention-thiazide diuretic or similar type of agent
More severe heart failure-loop diuretics
Refractory edema-may respond to combination of a loop diuretic and thiazide diuretic
Must monitor electrolytes and kidney function frequently and use potassium replacement as indicated

20
Q

Spironolactone

A

Baseline BMP and F/U in 2-4 weeks
Evidence that aldosterone mediates some of the major effects of the renin-aldosterone-angiotension system activation, such as myocardial remodeling and fibrosis as well as sodium and potassium loss at the distal tubule
Should be considered as a neurohormonal antagonist rather than a potassium sparing diuretic
Counterindicated in renal failure, hyperkalemia and hyponatremia
Need frequent monitoring of electrolytes and kidney function

21
Q

Digoxin

A

Use of digoxin has declined
Lacks the benefits of the neurohormonal antagonists
Safety concerns secondary to high incidence of toxicity
Efficacy in decreasing the symptoms of heart failure has been established
Must monitor levels for toxicity and dose adjust in patients with renal impairment

22
Q

Antiarrhythmic Therapy

A

Use of antiarrhytmic tx has declined d/t permanent pacers
Patients with moderate to severe heart failure have a high incidence of symptomatic and asymptomatic ventricular arrhythmias
70% of patients have asymptomatic nonsustained ventricular tachycardia
<10% of patients have syncope or presyncope related to ventricular tachycardia
Empiric antiarrhythmic therapy does not improve survival and beta blockers should be used for these patients

23
Q

Nonpharm Tx

A
Birventricular pacing for EF <0.12 msec
Implantable cardioverter defibrillators
Case management, diet and exercise training
Coronary revascularization
Cardiac transplantation
Left-ventricular assist devices
Palliative care
24
Q

Treatment Stage A

A
At risk for heart failure without structural heart disease or symptoms of heart failure
Treat hypertension
Smoking cessation
Treat lipids
Exercise
Discourage alcohol or drug use
Control metabolic syndrome
ACE inhibitors in appropriate patients
25
Q

Treatment Stage B

A

Structural heart disease without signs of heart failure
All measures under A
ACE inhibitors or ARBs in appropriate patients
Beta blockers in appropriate patients
Devices in selected patients such as biventricular pacemakers or ICDs

26
Q

Treatment Stage C

A

Structural heart disease with prior or current symptoms of heart failure
All measures in A & B
Dietary salt restrictions
Routine use of diuretics, ACE, and beta blockers
In selected patients consider digoxin, aldactone, hydralazine and nitrates, ARBs
Devices in selected patients such as ICDs and biventricular pacemakers

27
Q

Treatment Stage D

A

Refractory heart failure requiring specialized interventions
All A, B, and C measures
Decision regarding appropriate level of care
Compassion or end-of life care
Extraordinary measures such as heart transplantation, chronic inotropic support, permanent mechanical support such as left-ventricular assist devices, and experimental drugs or treatments

28
Q

Special Considerations

A

Most patients with a new diagnosis of heart failure should be referred to cardiology
Most patients with a new decreased ejection fraction should be referred to cardiology for an ischemic evaluation by cardiac catherization or in some cases stress testing
Most patients with vavular heart disease should be referred to cardiology
Do not stop ACE inhibitors or beta blockers in heart failure patients for ASYMPTOMATIC low blood pressure
Remember that diuretics are for symptom relief only and have no survival benefit. Use the lowest dose that keeps the patient comfortable from fluid retention in order to be able to maximize beta blockers and ACE inhibitors